IP6K1 and Obesity: Therefore, unlike therapeutic interventions that target PPARG and LEPR activity, which yield detrimental side effects including increased fracture risk and altered feeding behavior, respectively, the inhibition of IP6K1 maintains insulin sensitivity and prevents obesity while preserving bone integrity.